Literature DB >> 14744769

Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma.

Jen-Liang Su1, Jin-Yuan Shih, Men-Luh Yen, Yung-Ming Jeng, Cheng-Chi Chang, Chang-Yao Hsieh, Lin-Hung Wei, Pan-Chyr Yang, Min-Liang Kuo.   

Abstract

Cyclooxygenase (COX)-2, the inducible isoform of prostaglandin H synthase, has been implicated in the progression of human lung adenocarcinoma. However, the mechanism underlying COX-2's effect on tumor progression remains largely unknown. Lymphangiogenesis, the formation of new lymphatic vessels, has recently received considerable attention and become a new frontier of tumor metastasis research. Here, we study the interaction between COX-2 and the lymphangiogenic factor, vascular endothelial growth factor (VEGF)-C, in human lung cancer cells and their implication in patient outcomes. We developed an isopropyl-beta-D-thiogalactopyranoside-inducible COX-2 gene expression system in human lung adenocarcinoma CL1.0 cells. We found that VEGF-C gene expression but not VEGF-D was significantly elevated in cells overexpressing COX-2. COX-2-mediated VEGF-C up-regulation was commonly observed in a broad array of non-small cell lung cancer cell lines. The use of pharmacological inhibitors or activators and genetic inhibition by EP receptor-antisense oligonucleotides revealed that prostaglandin EP(1) receptor but not other prostaglandin receptors is involved in COX-2-mediated VEGF-C up-regulation. At the mechanistic level, we found that COX-2 expression or prostaglandin E(2) (PGE(2)) treatment could activate the HER-2/Neu tyrosine kinase receptor through the EP(1) receptor-dependent pathway and that this activation was essential for VEGF-C induction. The transactivation of HER-2/Neu by PGE(2) was inhibited by way of blocking the Src kinase signaling using the specific Src family inhibitor, PP1, or transfection with the mutant dominant negative src plasmid. Src kinase was involved in not only the HER-2/Neu transactivation but also the following VEGF-C up-regulation by PGE(2) treatment. In addition, immunohistochemical staining of 59 lung adenocarcinoma specimens showed that COX-2 level was highly correlated with VEGF-C, lymphatic vessels density, and other clinicopathological parameters. Taken together, our results provided evidence that COX-2 up-regulated VEGF-C and promotes lymphangiogenesis in human lung adenocarcinoma via the EP(1)/Src/HER-2/Neu signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744769     DOI: 10.1158/0008-5472.can-03-1301

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

Review 1.  Crosstalk of oncogenic and prostanoid signaling pathways.

Authors:  Rolf Müller
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

Review 2.  Myeloid cells and lymphangiogenesis.

Authors:  Adrian Zumsteg; Gerhard Christofori
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

3.  Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells.

Authors:  Shun-Fa Yang; Mu-Kuan Chen; Yih-Shou Hsieh; Tsung-Te Chung; Yi-Hsien Hsieh; Chiao-Wen Lin; Jen-Liang Su; Ming-Hsui Tsai; Chih-Hsin Tang
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

4.  EP1 prostanoid receptor coupling to G i/o up-regulates the expression of hypoxia-inducible factor-1 alpha through activation of a phosphoinositide-3 kinase signaling pathway.

Authors:  Ruyue Ji; Chih-Ling Chou; Wei Xu; Xiao-Bo Chen; David F Woodward; John W Regan
Journal:  Mol Pharmacol       Date:  2010-03-24       Impact factor: 4.436

Review 5.  Lymphangiogenesis and lymphatic vessel remodelling in cancer.

Authors:  Steven A Stacker; Steven P Williams; Tara Karnezis; Ramin Shayan; Stephen B Fox; Marc G Achen
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

6.  Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-alpha converting enzyme.

Authors:  Mazin A Al-Salihi; Scott C Ulmer; Thao Doan; Cory D Nelson; Tracy Crotty; Stephen M Prescott; Diana M Stafforini; Matthew K Topham
Journal:  Cell Signal       Date:  2007-05-23       Impact factor: 4.315

7.  Sinomenine inhibits proliferation of SGC-7901 gastric adenocarcinoma cells via suppression of cyclooxygenase-2 expression.

Authors:  Yifei Lv; Changshun Li; Shuang Li; Zhiming Hao
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

Review 8.  Molecular mechanisms of lymphangiogenesis.

Authors:  Meiko Takahashi; Takanobu Yoshimoto; Hajime Kubo
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

Review 9.  Potential therapeutic strategies for lymphatic metastasis.

Authors:  Bernadette M M Zwaans; Diane R Bielenberg
Journal:  Microvasc Res       Date:  2007-09-19       Impact factor: 3.514

10.  Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells.

Authors:  Ju-Fang Liu; Yi-Chin Fong; Chih-Shiang Chang; Chun-Yin Huang; Hsien-Te Chen; Wei-Hung Yang; Chin-Jung Hsu; Long-Bin Jeng; Chih-Yi Chen; Chih-Hsin Tang
Journal:  Mol Cancer       Date:  2010-02-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.